Mivebresib(ABBV-075）
产品编号: DC9836
Featured
我们的合作伙伴:
中国地区超过5000个高品质化合物库存
应用领域
Mivebresib是一种有效且可口服的溴结构域和末端结构域 (BET) 抑制剂。 Mivebresib与 BRD4结合的 Ki 为1.5 nM。
| Cas No.: |
1445993-26-9 |
| 名称: |
|
| 别名: |
ABBV-075; ABBV075; ABBV 075 |
| SMILES: |
CCS(=O)(=O)NC1=CC(=C(C=C1)OC2=C(C=C(C=C2)F)F)C3=CN(C(=O)C4=C3C=CN4)C |
| 分子式: |
C22H19F2N3O4S |
| 分子量: |
459.47 |
| 纯度: |
|
| 保存条件: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: |
|
| In Vivo: |
|
| In Vitro: |
|
| References: |
Mivebresib is a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo. Also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins. Mivebresib inhibit DHT-stimulated transcription of AR target genes without significant effect on AR protein expression. In addition to blocking the transcription activation downstream of AR, Mivebresib is also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins. |
| Kinase Assay: |
|
| Cell Assay: |
|
| Animal Administration: |
|
| References: |
|
MSDS
COA
| LOT NO. |
DOWNLOAD |
|
|
| 2018-0101 |
|
询盘
